Epigenetic modification by 5-Aza/TSA treatment induces loss of B-cell phenotype in B-cell derived non-Hodgkin lymphoma
10.3969/j.issn.1000-4718.2018.01.009
- VernacularTitle:5-Aza/TSA表观遗传处理诱导非霍奇金淋巴瘤B细胞表型丢失
- Author:
Jing DU
1
;
Feng WANG
;
Qian ZHANG
;
Wei-Wei CHEN
;
Juan-Juan DAI
Author Information
1. 滨州医学院附属医院 肿瘤研究中心
- Keywords:
Non-Hodgkin lymphoma;
Hodgkin lymphoma;
B-cell phenotype;
Epigenetics;
5-Aza-2 '-deoxy-cytidine;
Trichostatin A
- From:
Chinese Journal of Pathophysiology
2018;34(1):52-57
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To investigate influence of demethylation/acetylation by 5-Aza-2'-deoxycytidine/trichostatin A(5-Aza/TSA)treatment on B-cell specific phenotype of non-Hodgkin lymphoma cells.METHODS:CD19 promoter-driven reporter with NEO cassette was constructed to realize transfection and stable selection of Hodgkin and non -Hodgkin lymphoma cells.The exogenous CD19 promoter activity in both cell line clusters with and without 5-Aza/TSA treatment was detected and compared.The B-cell specific expression profiling in Eμ-myc transgenic mouse model developed lymphoma was isolated and identified.The effects of 5-Aza/TSA treatment on B-cell specific phenotype were analyzed.RESULTS:Epigenetic modification via 5-Aza/TSA repressed B-cell specific phenotype in B-cell-derived non-Hodgkin lymphoma cells. CONCLUSION:Epigenetic modification of pivotal master repressor genes plays an essential role in B -cell phenotype of both human and murine developed B-cell non-Hodgkin lymphoma cells.
